The easy part

GlaxoSmithKline’s new boss, Andrew Witty, takes over in May. There’s a simple way for him to make his mark on the $150 billion drugs giant - stop selling soda and toothpaste. About 15% of Glaxo’s sales come from selling such consumer products. Yet there are few marketing, production or developmental synergies between making innovative cancer treatments and Polident denture adhesive or Horlicks, the malt beverage beloved by Britain’s senior set. Separating the consumer business - either through...